Evidence of the safety and protective benefits of human papillomavirus virus (HPV) vaccines as an anti-cancer measure is overwhelming. However, vaccine uptake varies widely across countries and falls short of levels needed to achieve population immunity. We highlight policy measures that would help ensure greater worldwide coverage and save lives.
HPV Vaccines: A Preemptive Strike in the War on Cancer
Childhood immunization programs prevent up to three million deaths globally per year, but that number could be increased by a further 1.5 million if optimal vaccination coverage could be achieved. Despite efforts through The Global Vaccine Action Plan endorsed by Ministers of Health from 194 countries in May 2017, the World Health Organization's goals to improve immunization coverage worldwide continue to face considerable challenges.
There is overwhelming evidence that human papillomaviruses (HPV) are responsible for diverse preventable cancers, accounting for 4.5% of all new cancers occurring worldwide (de Martel et al., 2017) . Extensive clinical testing and postmarket experience have shown that HPV vaccines deliver safe and durable protection against these tumorigenic viruses (Huh et al., 2017) . However, despite compelling objective evidence of benefit, vaccination rates and policies differ markedly in different countries consequent to apparent happenstance. In this article, we focus on strategies that should further promote wider protective HPV immunization.
Human Papillomavirus Causes Cancers
Anogenital human papillomaviruses are among the most common sexually transmitted infections, with tens of millions of new cases per year globally. The majority of infections are eliminated by the host immune system within 2-3 years. However, HPV infections that evade the immune response and promote proliferation of mucoepithelial tissues can have serious long-term health consequences. Of the more than 170 genotypes identified to date, types 16 and 18 are associated with the majority of HPV-related tumors, which include cervical, vulvar, penile, anal, and oropharyngeal tumors, as well as precancerous and dysplastic lesions. Of these, cervical cancer represents the greatest global health burden, as it is the fourth most common cancer in women and a leading cause of cancer mortality in the developing world (over a quarter of a million deaths per annum, Figure 1 and http://globocan.iarc.fr/old/FactSheets/ cancers/cervix-new.asp). The link between viral infection and urogenital/ oropharyngeal cancer was first identified nearly a half century ago, but effective preventative measures have only been available since the introduction of the first prophylactic vaccines against HPV. Akin to the implementation of worldwide neonatal hepatitis B vaccination, HPV vaccination should be viewed primarily as an anti-cancer measure, and one that will pay the largest health dividends in one of the world's most vulnerable and disadvantaged populations: women in the Global South.
Since 2006, Gardasil, the first approved HPV vaccine, has offered protection against both HPV-16 and -18, reducing the risk of HPV-related neoplasms by 60%-70% on completion of a course of two or three vaccine doses. Gardasil additionally confers immunogenicity against HPV serotypes 6 and 11, which are causative of anogenital warts and associated with a persistent airway infection known as recurrent respiratory papillomatosis. Subsequently approved HPV vaccines provide either narrower (Cervarix) or broader (Gardasil 9) spectrums of coverage against HPV serotypes, although each are similarly effective against the serotypes most commonly associated with cancers. Gardasil 9, which was approved by the US Food and Drug Administration (FDA) in 2014, protects against nine of the most pathogenic strains, accounting for approximately 90% of all cervical cancer cases, and is likely to become the preferred vaccine in many countries.
The Safety of HPV Vaccination Is Well Established
A massive body of evidence supports the safety of HPV vaccines. All such vaccines are made using viral structural proteins produced using recombinant techniques. The vaccines comprise purified L1 capsid protein of the relevant papillomavirus genotypes, together with standard vaccine adjuvants of proven safety. No viral genes that enable papillomavirus reproduction or cell transformation are incorporated in the manufacturing process. In a study of nearly one million vaccine recipients, researchers in Denmark and Sweden found no association between immunization with quadrivalent HPV vaccine and autoimmune, neurological, or thromboembolic adverse reactions (ArnheimDahlströ m et al., 2013) . A UK study of more than 10 million girls vaccinated against HPV likewise found no increased risk of Guillain-Barré syndrome (Andrews et al., 2017) , which had anecdotally been reported as a possible adverse effect in other countries. The World Health Organization (WHO) estimates that over 270 million doses of HPV vaccines have been delivered since the approval of Gardasil in 2006. With the exception of transient syncope, a common anxietyrelated side effect of many vaccines, and rare cases of anaphylaxis, the WHO vaccine safety committee found no association of HPV vaccination with serious adverse events (http://www.who. int/vaccine_safety/committee/topics/hpv/ June_2017/en/).
HPV Vaccine Uptake Is All Over the Map
The uptake of HPV vaccines has varied dramatically across countries and regions. The reasons for this are complex, and span both biological and social considerations. The mode of transmission (mainly through intimate contact), age of vaccine administration (adolescence), the time lag between infection and cancer onset (often decades), and the gender distribution of HPV-associated cancers (primarily female) all distinguish HPV vaccines from more familiar pediatric vaccines that protect against casually-transmitted childhood infectious diseases.
Cultural factors also affect public sentiment surrounding HPV vaccines. These range from sensationalist coverage of suspected adverse incidents in public and social media, to questions of cost and access, to suspicions of pharmaceutical company motives, to religious or moral concerns over vaccination of juveniles as they near the age of sexual maturity. Questions of balancing individual autonomy against collective benefit have prompted philosophical and ethical debates, many of which have focused on the question of whether anti-HPV programs, like many other immunization efforts, should include a vaccination mandate (Colgrove 2006) . Additionally, debates have concerned whether, and under what conditions, people objecting to vaccines should be permitted to opt out. The latter question is of particular relevance in the United States, where state laws allowing religious and philosophical exemptions to mandatory vaccines are common.
Local and national governments have shown highly variable responses to the challenges of public education and trustbuilding. The result has been tremendous variability in HPV vaccine uptake even in countries at similar levels of economic development. Globally, full-course vaccination rates for young women in developed economies stand at around one in three (Bruni et al., 2016) . Through the enactment of ''no-jab, no-pay'' and ''no-jab, no-play'' laws, which make vaccination a prerequisite for school registration, payment of childcare benefits, and other public benefits, Australia has achieved more than 70% coverage for all mandated pediatric vaccines among school-age children. The success of such programs may be instructive for measures intended to raise HPV vaccine coverage.
In the UK, where their National Health Service covers HPV vaccines, more than 88% of 12-to 13-year-old females have completed the vaccination course. Yet in the United States, where the first HPV vaccine was introduced, over half of eligible teens have not completed the recommended vaccination series, although there have been gradual improvements. In some parts of the USA, coverage remains below 15%, influenced by factors including urban residence, poverty, ethnicity, insurance, completion rates, and state-based policies. Similarly, the European Union shows highly variable coverage among its member states, with the highest rates in Northern Europe, but much lower coverage in several other regions, leaving less than 40% of the target population in EU covered by a full HPV vaccination course (Bruni et al., 2016) .
In Japan, the Ministry of Health, Labour and Welfare flinched after unverified media reports of vaccine side effects including motor and cognitive disorders, withdrawing its active recommendation for HPV vaccination in 2013, which led to the withdrawal of the vaccines from the national health insurance scheme. This led to a dramatic loss of public confidence, resulting in plummeting vaccination rates from around 70% to just 0.6% of the target population (Hanley et al., 2015) . A 2015 follow-up study of 2,584 reported adverse reactions, among 3.38 million persons vaccinated, identified only 186 cases (<0.006%) that had not spontaneously resolved (Ministry of Health Labor and Welfare http://www.mhlw.go.jp/bunya/ kenkou/kekkaku-kansenshou28/chousa/ dl/160212_02.pdf). Importantly, no causeeffect relationship linking adverse reactions to the vaccine was established. That notwithstanding, the Ministry's noncommittal stance and the lack of reimbursement remain unchanged, and uptake of HPV vaccination in Japan consequently continues to be extremely low for an advanced economy.
The global repercussions of Japan's equivocation are grave, having provided anti-vaccination groups with what they claim to be evidence of the harms of a safe vaccine (Larson et al., 2014) . The safety question is now making its way through the nation's courts, with more than 100 young women suing both the government and the vaccine manufacturers for compensation over claims of adverse effects, including chronic pain and debility. A second legal case centers on a scientific dispute. A Japanese academic scientist is suing a physician-journalist for defamation over her claims that he misled the public about the safety of the HPV vaccine by reporting that it caused brain damage in mice. The study was called into question when medical journalist, Dr. Riko Muranaka, discovered that it involved only a single mouse each in the active and control groups, and that moreover the slides presented to the media did not even show the brain of the mouse that had received the vaccine. Muranaka was awarded the 2017 John Maddox Prize for her work championing HPV vaccination, a valuable recognition of her courage in taking a stand against vaccine fear-mongering.
Challenges and Opportunities in the Global South
In developing countries, the situation is, with notable exceptions, even less reassuring. By 2016, only 2.7% of females aged 10-20 years in low and lower-middle income countries had received a full HPV vaccine course (HPV Information Centre http://http://www.hpvcentre.net/statistics/ reports/XWX.pdf). This is especially concerning given the higher incidence and mortality of HPV-associated cancers in such regions, especially cancer of the cervix. In many countries, the lack of HPV screening options, such as national Pap smear programs, further compounds the cancer risk in adult women. In light of the health burden of HPV-related disease, the WHO has issued a series of recommendations for the introduction of low-cost HPV vaccines in developing countries, paying particular attention to the need for effective messaging and educational strategies for HPV vaccine rollout.
The combination of high manufacturing cost relative to other vaccines, communications, and cultural factors has nonetheless left much of the developing world underserved. Similar to Japan, India experienced a challenge to public trust over questions about the deployment of a vaccination program by an international health organization in 2010. The resultant HPV vaccine hesitancy lingers even today, although some progress has been made in broadening coverage in a number of Indian states. The Chinese government has also been very conservative in its review of HPV vaccines, the first of which was only approved in 2017. A public crisis of confidence over the deaths of several infants who had been vaccinated against hepatitis B in 2013 may have contributed to the delay. Notably, as was the case for HPV vaccines in Japan, the Chinese Food and Drug Administration found that the deaths were not caused by the hepatitis B vaccine; however, not before public confidence in vaccines was damaged by widespread misinformation and finger-pointing on social media (Chen et al., 2015) .
Despite these substantial challenges, some developing nations have attained high rates of HPV vaccination. The government of Rwanda, working with the US Centers for Disease Control (CDC) and Merck, the maker of Gardasil, succeeded in delivering full-course coverage to 93.3% of girls in primary grade six through a school-based program with no out-ofpocket payment. In Bhutan, a national vaccination program endorsed by that country's monarch has achieved threedose coverage rates of > 90% in adolescents (Dorji et al., 2015) . Low-and no-cost programs have been introduced in numerous other developing regions as well, either through direct negotiations with vaccine manufacturers or through private philanthropic efforts. These success stories highlight the key importance of establishing local champions in encouraging HPV vaccination.
It has been estimated that around 380,000 cases of cancer could be avoided by 2080 in the 118 million women who were fully vaccinated against HPV worldwide. Countries that succeed in introducing effective HPV vaccination programs deliver lifelong health benefits to individual vaccine recipients and contribute to national health through increases in population immunity. Those that fail to do so risk unnecessarily exposing generations of young women and men to preventable virus-associated cancers and other serious diseases. The outcomes attributable to differences in national health policy stand in stark relief; lessons can be learned from both the successes and failures in safeguarding populations against HPVs, and have clear implications for vaccination programs targeting other microbial and viral infections.
Despite the availability of effective prophylaxis against a spectrum of HPVassociated cancers and other diseases, vaccine uptake worldwide remains inadequate. Most ill-health due to HPV falls disproportionately on reproductive-age women in the developing world. This represents a policy challenge, as much as a scientific one. We suggest below a number of measures that should help governments, vaccine providers, and philanthropic organizations establish and maintain public confidence in HPV vaccine safety and efficacy, and in their efforts to reduce the global health burden of HPV-associated disease.
Overcoming the Barriers to Global HPV Vaccination Uptake A 2016 systematic review of peer reviewed behavioral, informational, and social interventions designed to improve adolescent HPV vaccination rates found that measures designed to increase access and availability are the most effective (Walling et al., 2016) . School-based programs have shown particular promise. And it comes as no surprise that reducing the financial burden to recipients translates into higher uptake. However, educational interventions demonstrate relatively minimal effects on sustaining vaccination behavior. Stakeholder groups should thus make coordinated efforts to increase access and availability especially targeting both providers and vaccine recipients. Very high levels of immunization coverage are achievable with low/no cost, schoolbased programs. In Figure 2 we highlight some policy measures designed to promote widespread uptake of global HPV vaccines.
Containing Costs and One-Shot Delivery
In many developing-world countries no public health programs are currently targeted to adolescents at an appropriate age for HPV vaccine delivery. Consequently the addition of a new program to deliver HPV vaccines would be expensive and logistically challenging. Consideration has therefore been given to adding the HPV vaccine to existing pediatric vaccine programs, but evidence for adequate duration of protection will be required and will take decades to establish. There is good evidence that HPV vaccines given to adolescents provide sufficient duration of protection against infection following two immunizations, and gathering evidence that a single dose may provide up to seven years protection against infection (Safaeian et al., 2018) . As further data accrues, support for, a single dose mass immunization campaign may break the tragic and preventable cycle that links this sexually transmitted infection with cancer.
Positive Health Messages to Counter Fear, Uncertainty, and Doubt Communication efforts to promote greater HPV vaccine uptake should be focused beyond the simple provision of accurate and understandable information to the families of adolescents in the targeted age group for HPV immunization. It is essential that the perception of these vaccines within local contexts be addressed. The WHO and the US CDC have published recommendations designed to help vaccine stakeholders craft effective messages to enhance uptake. These include continuing education courses for medical providers, public education materials for parents and media, and HPV references to other informational resources. Such materials need to be tailored to many distinct national contexts, which will require coordination and funding support-thereby providing a clear opportunity for health organizations with a developing world focus.
Effective counter-messages against misconceptions and misinformation are also needed. The incontrovertible evidence for their safety notwithstanding, HPV vaccine manufacturers and advocates have faced vocal opposition from well-coordinated anti-vaccination groups. Serious conditions incorrectly attributed to HPV immunization include multiple sclerosis, leukemia, and chronic pain (Offit, 2011) . The lack of evidence to support these claims is frequently attributed to a conspiracy by vaccine makers, government bureaucrats, public health workers, and academics to suppress reports of harm. Some religious groups have further raised concerns that vaccination of young people nearing the age of sexual maturity may somehow lead them to engage in more casual sexual behavior. Such thinking can result in actual harms, not only for children who fail to gain protection against preventable cancers, but on the broader community through reductions in vaccine uptake needed to achieve herd immunity. Increasing HPV vaccine uptake in countries of greatest need will require policy measures including cost containment, local champions, education and messaging, and support for further research into singledose vaccination regimes.
Clear and accurate messaging about the benefits of HPV immunization is centrally important to countering misinformation and public uncertainty. Parents are apt to be influenced in their decisions by frightening stories of vaccine harm, no matter the source. The effect is amplified by the media-savvy efforts of anti-vaccine groups (which often style themselves misleadingly as ''vaccine safety'' organizations). In the United States in particular, scare mongering about HPV vaccines has taken hold among a surprising number of film and TV celebrities, who lend further artificial authority to the movement. The damage is not limited to the US, as the internet affords a global megaphone to distort and disseminate such messages based on cultural context. For example, among some African expatriates in the UK, HPV vaccine has come to be viewed not only as risky to health and sexual mores, but also as part of a plot to sterilize young African women (Mupandawana and Cross, 2016) . Given the much higher incidence of, and mortality due to, cervical cancer in developing economies, the scare tactics deployed by developed world anti-vaccine organizations are even more pernicious. In such countries, communications efforts must work with trusted health partners at the local level to develop and deploy messages that accurately convey the benefits of vaccination.
In the first world, pushing back against the misinformation and doubt spread by opponents of HPV vaccination is also an important, although unfortunately sometimes thankless, mission. Scholars of vaccine history such as Paul Offitt and anonymous science bloggers such as the authors of skepticalraptor.com and respectfulinsolence.com provide an important public service by confronting, contextualizing and debunking false stories about alleged HPV vaccine harm. Research and medical institutions need to do more to encourage these kinds of engagement, especially in contentious areas of public health debate and misunderstanding of science. Human papillomavirus vaccination programs stand poised to eliminate a deadly threat to the health of women and men around the world. We would all do well to shout a little louder about their value.
Toward a Future Free of HPV Cancers Raising HPV vaccine coverage will require well-coordinated, long-term programs with strong financial and logistic support from both governmental and non-governmental organizations. These will necessarily entail identifying and implementing effective measures on the scientific, clinical, public health and regulatory fronts, with a focus on enhancing greater access and public understanding (Frazer, 2018) . To be effective, vaccine programs must be supported by sufficient funding, stable government policies, vocal national champions, adequate infrastructure to enable delivery to school-age children, and educational and informational programs on the safety and efficacy of these vaccines. With such measures in place, near-universal immunization at levels needed to confer herd immunity against HPV is an attainable goal. Having served the quest to eradicate avoidable cancers, cervical cancer screening programs may yet become a historical footnote if all women are immunized.
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